Highlights Alnylam Pharmaceuticals, Inc.

Equities

ALNY

US02043Q1076

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-06-05 pm EDT			After hours 06:10:43 pm
303.05 ^USD	-0.19%		294.96	-2.67%

Jun. 03	Alnylam, Inceptive sign up to $2 billion AI drug discovery deal	RE
Jun. 03	Alnylam Pharmaceuticals Strikes Up to $2 Billion AI Collaboration With Inceptive Nucleics	MT

Highlights

Jun. 03	Alnylam Pharmaceuticals Strikes Up to $2 Billion AI Collaboration With Inceptive Nucleics	MT
Jun. 03	Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics	CI
May. 12	Alnylam Pharmaceuticals, Inc. Announces New Analyses from the Helios-B Phase 3 Study of Vutrisiran in Patients	CI
Apr. 30	Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 30	Alnylam Pharmaceuticals Q1 Adjusted Net Income, Revenue Rise; Reiterates 2026 Product Revenue Guidance -- Shares Up Pre-Bell	MT
Apr. 30	(ALNY) Alnylam Pharmaceuticals Expects 2026 Total Net Product Revenue Range $4.90B - $5.30B	MT
Apr. 30	Earnings Flash (ALNY) Alnylam Pharmaceuticals, Inc. Reports Q1 Revenue $1.17B, vs. FactSet Est of $1.12B	MT
Apr. 30	Earnings Flash (ALNY) Alnylam Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $1.99 per Share	MT
Mar. 30	Alnylam Pharmaceuticals Announces New Data Supporting Benefits of Vutrisiran in Attr-Cm and Potential of Zilebesiran for Hypertension Management	CI
Mar. 24	Alnylam Pharmaceuticals, Inc. Advances ATTR-CM Care with Strategic Collaboration and AI-Enabled Pathways	CI
Mar. 24	Alnylam Pharmaceuticals, Viz.ai Collaborate on AI-Enabled Detection of Transthyretin Amyloidosis	MT
Mar. 02	Intellia gets FDA nod to resume second gene therapy trial after safety pause	RE
Feb. 12	Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
Feb. 12	Alnylam Pharmaceuticals Q4 Adjusted Net Income, Revenue Rise; Issues 2026 Outlook	MT
Feb. 12	Earnings Flash (ALNY) Alnylam Pharmaceuticals, Inc. Posts Q4 Adjusted EPS $1.25 per Share	MT
Feb. 12	Earnings Flash (ALNY) Alnylam Pharmaceuticals, Inc. Reports Q4 Revenue $1.10B, vs. FactSet Est of $1.15B	MT
Jan. 11	Alnylam Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2026	CI
Dec. 17	Alnylam Pharmaceuticals, Inc. Announces to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics	CI
Dec. 11	Alnylam announces partial repurchase of 1.00% convertible senior notes due 2027	RE
Dec. 11	Alnylam Pharmaceuticals Signs Redemption Deals for Certain 1% Senior Notes Due 2027	MT
Nov. 08	Alnylam Pharmaceuticals, Inc. Announces Results from New Post Hoc Analysis of the Helios-B Phase 3 Study of Vutrisiran	CI
25-10-30	Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-30	Alnylam Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2025	CI
25-10-30	Alnylam beats Q3 revenue estimates, up FY forecast	RE
25-10-30	Alnylam Pharmaceuticals Swings to Q3 Non-GAAP Earnings, Revenue Increases	MT